Today the Supreme Court heard arguments in Texas v.
Azar that the Affordable Care Act (ACA)'s
individual coverage mandate is unconstitutional. According to
the ruling in the underlying case, in the absence of the individual
mandate, the rest of the ACA cannot stand.
While the consequences of striking down the ACA are vast, it
also includes putting the future of biosimilars in jeopardy.
By way of background, the Biologics Price Competition and
Innovation Act (BPCIA), was passed as part of the ACA to allow for
abbreviated biologics license applications to be filed for complex
products which are biosimilar to/interchangeable with FDA-licensed
biologics.
If the Supreme Court strikes down most — or all — of
the ACA, the regulatory pathway for biosimilars would essentially
disappear overnight. This would affect millions of patients
who would no longer see more affordable biosimilar versions of
high-cost biologic treatments reach the market.